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 Abstract 
 Proteomics studies typically aim to exhaustively detect 
peptides/proteins in a given biological sample. Over the 
past decade, the number of publications using pro teomics 
methodologies has exploded. This was made possible 
due to the availability of high-quality genomic data and 
many technological advances in the fields of microflu-
idics and mass spectrometry. Proteomics in biomedical 
research was initially used in  ‘ functional ’ studies for the 
identification of proteins involved in pathophysiological 
processes, complexes and networks. Improved sensitivity 
of instrumentation facilitated the analysis of even more 
complex sample types, including human biological fluids. 
It is at that point the field of clinical proteomics was born, 
and its fundamental aim was the discovery and (ideally) 
validation of biomarkers for the diagnosis, prognosis, or 
therapeutic monitoring of disease. Eventually, it was rec-
ognized that the technologies used in clinical proteomics 
studies [particularly liquid chromatography-tandem mass 
spectrometry (LC-MS/MS)] could represent an alternative 
to classical immunochemical assays. Prior to deploying 
MS in the measurement of peptides/proteins in the clini-
cal laboratory, it seems likely that traditional proteo mics 
workflows and data management systems will need to 
adapt to the clinical environment and meet in vitro diag-
nostic (IVD) regulatory constraints. This defines a new 
field, as reviewed in this article, that we have termed 
quantitative Clinical Chemistry Proteomics (qCCP). 
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 Introduction 
 The study of pathophysiological mechanisms is the basis 
of the selection/discovery of most clinical biomarkers 
used for the diagnosis or the monitoring of diseases. The 
ability to discover and use biomarkers is heavily depend-
ent on technological developments to select, validate, 
and quantify them in biological fluids and tissues. Among 
these developments, we can cite the  ‘ omics ’ technologies 
represented by genomics and the so-called post-geno-
mics approaches (e.g., proteomics). Unbiased proteomics 
studies, which typically aim to exhaustively detect 
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peptides/proteins in a given biological sample, were an 
important focus over the past decade [1 ]. This is explained 
by the availability of extensive genomic data, by techno-
logical advances in the field of micro- and nanotechnolo-
gies, and in the development of robust mass spectrometry 
(MS) methods [2 ]. Indeed, recent improvements in MS 
technology have achieved better sensitivity, specificity, 
and throughput. However, as with any innovative technol-
ogy, translation from research to clinical use is a signifi-
cant challenge [3 ]. Not only are there analytical considera-
tions to be taken into account, but the feasibility of the 
approach in a hospital environment, the compliance with 
regulatory constraints, and the medical benefit vs. the 
monetary cost must also be considered. MS has demon-
strated its clinical potential, e.g., in the field of small mol-
ecules, where its analytical capabilities and low cost have 
helped dethrone other approaches. In the area of quan-
titative analysis of peptides/proteins in biological fluids, 
which is the subject of this review, we believe that MS is 
poised to supplant traditional methods of immunochemi-
cal quantification of proteins. This will lead to a signifi-
cant proliferation of methods to quantify biomarkers that 
will mark the start of a new field that we term quantitative 
Clinical Chemistry Proteomics (qCCP). 
 General characteristics of qCCP 
 qCCP, which must be viewed as a usable clinical applica-
tion of the detection and quantification of proteins by 
MS, is easily differentiated from the other uses of MS 
in proteomics. To understand these differences, which 
go beyond purely analytical considerations, it might be 
interesting to review the history of the use of proteo-
mics in the field of biology. In fact, once MS methods 
of peptides/proteins analysis were commonly avail-
able, the use first turned to the identification of proteins 
isolated during various biochemical purification, sepa-
ration and fractionation methods. MS as a tool of identi-
fication has an essential role in biological research. This 
includes, e.g., the search for interacting protein partners 
[4 ], the analysis of biological complexes (e.g., transcrip-
tional, enzymatic, signaling), and [5 ] most often follow-
ing co-purification and separation with gel electropho-
resis. Increases in MS sensitivity allowed one to focus on 
post-translational modifications (e.g., phosphorylation, 
oxidation) whose identification might help in the under-
standing of pathophysiological mechanisms. 
 The increase in sensitivity went hand in hand with 
more complete coverage of the proteome (i.e., the ability 
to detect low abundance proteins) [6 ], which led to the 
development of catalogs of proteins present in a given type 
of clinical sample (e.g., urine, serum, cerebrospinal fluid). 
However, the goal of being extensive is not necessarily 
useful from the perspective of clinical chemistry laborato-
ries. Instead, in clinical proteomics, the different concen-
trations of peptides/proteins in normal vs. pathological 
conditions define new biomarkers. The technology used 
to identify differences in concentration is not important, 
but quantitative differences must be identifiable. Often 
proteomics experiments provide a relative quantification 
[7 ], strongly dependent on a series of experiments con-
ducted in a short-time interval and in a specific analytical 
context. Experiments such as these have led to the identi-
fication of many potential biomarkers. Yet the vast major-
ity of these biomarkers have never reached clinical use. 
It is not the purpose of this article to discuss this issue, 
but we can say that preanalytical biases, the relevance of 
initial clinical questions, the selection and phenotyping 
of patient groups, and the lack of appropriate validation 
phases are all elements that explain the poor success of 
the initially selected candidate biomarkers. As presented 
in this review, quantitative Clinical Chemistry Proteomics 
(qCCP) goes far beyond what has been previously termed 
 ‘ clinical pro teomics, ’ and has rigorous preanalytical, ana-
lytical and post-analytical constraints than enable the 
use of results in patient care. Of note, the expertise of the 
scientists involved in different stages of proteomic assay 
development is disparate; physicists for the design of 
machines; chemists who have used MS to quantify small 
molecules; basic science researchers interested in cata-
loging/the initial characterization of biological mixtures; 
those involved in the search for biomarkers; and finally 
clinical biologists (pathologists) trying to make qCCP a 
reality in patient care. All of these actors have different 
training/knowledge and sometimes there exist real diffi-
culties in speaking a common language. 
 qCCP workflow 
 It is imperative that the final qCCP workflow parallels that 
of conventional analyses in clinical chemistry. As a result, 
one must immediately identify approaches, processes, 
and conditions that are compatible with a clinical setting 
for logistical, organizational, technical, and financial 
reasons. This is covered in great detail in  section “Criteria 
for selecting analytes for qCCP”. A global vision of qCCP/
clinical workflow is illustrated in  Figure    1 . Indeed, the 
sample preparation in MS is only a part of a larger process 
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in which each step is important. Any one step that causes 
variability or limited throughput and the entire procedure 
would be affected. 
 Sample collection and initial 
preanalytics phases 
 Clinical specimens, in particular serum or plasma, are 
collected using various types of tubes: with or without 
separator gel, with or without different types of antico-
agulant, with different plastics. It is well-known that MS 
approaches can be sensitive to contaminants that are 
not relevant for classical immunological or enzymatic 
approaches [8 ]. As qCCP is a new way to use MS for clini-
cal chemistry, it will be important to try to identify inter-
ferences that stem from the choice of collection devices. 
On the other end, if a given qCCP analysis would need 
particular handling, e.g., the addition of a protease inhib-
itor cocktail, or the minimization of the time between 
collections and processing, this would certainly impair 
its clinical utility. Blood contains cellular elements and 
a high protein content while other samples have less 
protein and high salt concentration. Therefore, a first step 
of clean-up by centrifugation, filtration, or even dialysis 
could be needed. Altogether, as for any clinical analysis, 
qCCP will have to follow standardized protocol compat-
ible with common clinical workflows ( Figure   1 ). 
 Specific preanalytical procedures 
linked to qCCP 
 Almost all qCCP analyses involve a method of pretreatment 
of complex samples that includes enzymatic digestion to 
generate proteotypic peptides [9 ] and/or prefractionation 
steps. The aim of the prefractionation is to reduce sample 
complexity and concentrate the analytes. There are various 
methods for the preparation of patient samples prior to 
analysis by MS [10 ]. The selection of the method relies pri-
marily on the chemical characteristics of measured ana-
lytes (e.g., pI, hydrophobicity, and molecular weight), if 
the analytes are strongly bound to proteins, and the type 
of sample chosen for analysis (e.g., serum, urine). Several 
techniques have been described such as solid phase extrac-
tion (SPE), ion exchange, liquid-liquid extraction, depletion 
of major protein or immunocapture (see below). Whatever 
the sample matrix, to avoid interferences and errors, dif-
ferences between the analytes and the matrix components 
will determine the choice of the prefractionation method. 
 Enzymatic digestion 
 For quantification of a protein, the qCCP method generally 
relies on the detection and quantification of one or several 
peptides originating from selected analyte as surrogates 
for the protein concentration. In most cases, samples are 
 Figure   1   qCCP workflow. 
qCCP workflow will need to parallel that of conventional analyses in clinical chemistry. This includes preanalytical steps from specimen 
collection to specimen handling to analysis that all need to comply with the IVD regulatory requirement and post-analytical steps for which 
normal and pathological values may need to be established. 
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digested with trypsin, an enzyme that cleaves the protein 
specifically at the carboxyl end of the basic amino acids 
arginine and lysine [11 ]. The control of this step is critical to 
reduce variability linked to differential digestion between 
samples. Therefore, optimized protocols are needed to 
control enzyme-protein ratio, incubation time, composition 
of the digestion buffer and treatment preceding the diges-
tion step (e.g., reduction with dithiothreitol and alkylation 
with iodoacetamide). Importantly, internal standards can 
have value in monitoring this critical step (see paragraph 
“Quantitative measurement, standard and reference mate-
rial”). Direct analysis of the trypsin digest without addi-
tional sample fractionation is possible. This was the case in 
a work were 47 proteins were identified by direct analysis of 
signature peptides in trypsin digested plasma by liquid chro-
matography tandem MS (LC-MS/MS) with multiple reac-
tion monitoring (MRM) [12 ]. Their concentrations ranged 
from 1   mg/L to 55   g/L and approximate quantification was 
determined by using stable isotope-labeled standard (SIS) 
peptides [13 ]. Because validated external  calibration curves 
and/or standard addition experiments were not performed, 
it is not clear how accurate these measurements were. More 
recently, by using ultra-high performance LC coupled with 
high sensitivity MS/MS, as many as 67 proteins were iden-
tified simultaneously, still without the need for additional 
sample fractionation [14 ]. These experiments need addi-
tional validation steps that would help clarify the accuracy 
of the approach; however, they were an important demon-
stration that potentially useful data could be obtained from 
serum using LC-MS/MS. 
 In at least one study, quantification of clinically useful 
biomarker proteins in plasma by multiplexed LC-MRM/MS 
has demonstrated promise in the absolute quantification 
of biomarkers in plasma [15 ]. Using external calibration 
and comparison with existing clinical immunoassays for 
ApoA-I and ApoB, the authors confirmed that the direct 
analysis of tryptic digests is a viable approach, and may 
someday offer a cost-efficient and sample-saving analysis 
method for the clinical laboratory. 
 Protein precipitation 
 When the proteins or peptides of interest are of low mole-
cular weight, it may be possible to use simple protein pre-
cipitation for sample preparation. This approach takes 
advantage of the poor solubility of medium and large 
polypeptides in apolar solvents. It might be, however, 
difficult to standardize since variability can result from 
differences in total protein content of a given sample. By 
using a volatile solvent for precipitation, such as acetoni-
trile or acetone, the supernatant can be evaporated to 
produce a concentrated sample, thus improving analyti-
cal sensitivity. Other well-known precipitation reagents 
include trichloroacetic acid (TCA) and ammonium sul-
phate. Simple protein precipitation without trypsin clea-
vage has been used for biomarkers with clinical relevance 
(e.g., hepcidin-25 and insulin-like growth factor-1) [ 16 ,  17 ]. 
 Depletion of high abundance proteins (HAP) by 
immunoaffinity extraction. 
 Blood may be an excellent sample for both discover-
ing potential clinical biomarkers and for quantifying them 
clinically. However, the dynamic range of protein concen-
tration is known to be up to 12 orders of magnitude and 
the quantification of low abundance proteins remains a 
tremendous analytical challenge. HAP are present at the 
g/L level, with the most abundant being albumin (approx. 
40    g/L). On the other end of the concentration scale lie 
the low abundance proteins or peptides, e.g., cytokines, 
which are present at low ng/L. One possible solution for 
improving the limits of detection of low abundance pro-
teins is to deplete HAP by immobilized antibodies. There 
are commercially available low pressure LC type and spin-
filter type columns with immobilized antibo dies for as 
many as 20 HAP [18 ], making these products very popular 
in proteomics research for biomarker discovery [19 ]. 
Depletion of HAP may also be useful in qCCP, for improv-
ing the limits of detection of medium and low abundance 
proteins in clinical samples. HAP depletion has been 
reported to improve the reproducibility and increase the 
amount of sample that can be injected on column (approx. 
6-fold) compared to a direct analysis of non-depleted 
plasma protein samples [12 ]. The removal of peptides from 
albumin and other high abundant proteins also improves 
chromatographic peak shape of the lower abundance 
analytes of interest. It must be, however, recognized that 
analytes of interest may variably bind abundant proteins 
removed by anti-HAP antibodies leading therefore to inac-
curacy in measurement. 
 Solid phase extraction 
 Solid phase extraction   (SPE) is a common sample prepa-
ration technique for biological fluids in analytical chemi-
stry. It is based on adsorption chromatography with a 
range of chemical approaches ranging from simple hydro-
phobic or hydrophilic partition chromatography to ion-
exchange to immunoaffinity chromatography. It is a rapid 
sample preparation method used to selectively extract, 
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concentrate and purify target analytes prior to LC-MS/MS 
analysis [20 ]. Interferences are selectively removed from 
the column during a wash step and analytes of interest 
are eluted in a highly enriched extract. This prefractiona-
tion method has been used in qCCP for small endogenous 
peptides like hepcidin and  β -amyloid peptides without 
trypsin digestion (see  Table   1 ). 
 Analyte enrichment by 
immunoaffinity extraction 
 Extraction by immunoaffinity adsorbents has also been 
used to enrich analytes of interest from samples prior 
to MS analysis. Immunocapture involves specific non-
covalent binding interactions between antibodies and the 
protein or the peptide of interest [67 ]. The purified anti-
bodies are immobilized on a solid support, such as porous 
agarose or magnetic beads. Complex samples (e.g., serum, 
urine) are added to the solid support and target molecules 
bind specifically to the immobilized antibodies. After 
washing away non-bound matrix components, the cap-
tured target molecules are released from the ligand using 
generally a low pH buffer. The use of immunocapture 
before MS may, however, not completely overcome the 
limitation of immunoassays, which often lack specificity 
in many human samples [68 ]. Importantly, MS can detect 
many isoforms at once, as in the detection of  β -amyloid 
peptides in cerebrospinal fluid [69 ]. On-line immunoaffi-
nity extraction coupled with reversed phase LC-MS which 
allows the re-use of the columns was also utilized with 
amyloid-related peptides [70 ] and human chorionic gona-
dotropin [71 ]. 
 qCCP quality control and 
quality assurance 
 Clinical analyses must meet high-quality standards to 
ensure the quality of results delivered to care providers. To 
do this, one identifies and implements processes to avoid 
possible preanalytical errors that would cause the mis-
identification of samples or misleading results due to the 
conditions of specimen collection, specimen handling or 
specimen transfer. The integration of qCCP analyses into 
the laboratory management and information system could 
reduce these risks. The use of internal/external quality 
control is also essential. This helps ensure the quality of 
individual analyses but also allows longitudinal follow-up 
of patients. Proper clinical interpretation of qCCP results 
will depend on reference intervals, target ranges or medi-
cally relevant cut-off values based on control populations 
and variations due to pathophysiological processes of 
disease. Inaccuracies in qCCP measurement linked to 
interferences or lack of full specificity of the selected pep-
tides need also to be considered. 
 For qCCP analyses, which could replace conven-
tional immunochemical detection methods, concord-
ance studies to confirm the equivalence of the results will 
facilitate their use. In a number of cases, comparison of 
qCCP measures using MS and those using conventional 
methods may demonstrate non-equivalence. Indeed, the 
absolute quantification that allows qCCP is likely to reveal 
inaccuracies/bias of other methods that are more suscep-
tible to interferences or cross-reactivities. In these cases, 
as in cases where a new analyte will be measured by qCCP, 
a substantial number of samples from normal and patho-
logical populations will need to be analyzed prior to clini-
cal deployment. 
 Analytical MS approaches for qCCP 
 MS is an analytical technique that measures the mass (m) 
per charge (z) for a given ion (also termed the mass-to-
charge ratio,  m/z ). This technique allows the quantifica-
tion of ions of specific  m/z , generally by comparison with 
an internal standard. Mass spectrometers can combine 
various ionization methods and different ion separation 
methodologies to achieve measurements of varying mass 
accuracy and assay precision. 
 Matrix laser desorption ionization 
(MALDI) mass spectrometer 
 This approach uses a laser beam to desorb and ionize a 
sample/matrix mixture co-crystalized on a surface. Matrix 
molecules as well as samples get ionized in the gas phase 
by absorbing the energy transmitted by the laser, which 
results in their eruption from the plate surface. This mode 
of ionization generates mainly singly charged molecules. 
Matrix laser desorption ionization (MALDI) can be com-
bined with different MS methods [72 ], the most common 
being time-of-flight (TOF). TOF relies on an electric field to 
accelerate gas phase ions through a field-free path toward 
a detector. MALDI-TOF analyzers have a relatively unlim-
ited    m/z    range sensitivities and mass accuracies that 
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 Analytes  Clinical interest  Level of 
development 
 Technology  References 
 Brain natriuretic peptide (BNP-32)  Clinical biomarker for the diagnosis, 
prognosis and treatment of cardiac 
insufficiency (CI) 
 Clinical grade  FT-ICR  [21 ] 
 C-reactive protein  Marker for diagnosis of rheumatoid 
arthritis (inflammation) 
 Clinical grade  QqQ  [22 ] 
 Ceruloplasmin  Inborn error of metabolism, copper 
metabolism 
 Clinical grade  Q-TOF  [23 ] 
 Collagen type II peptide  Biomarker of osteoarthritis and 
matrix metalloproteinase activity 
 Clinical grade  QqQ  [24 ] 
 Glycohemoglobin (HbA 1c )  Long-term monitoring of blood 
glucose in diabetic patients 
 Clinical grade  ICP-MS, QqQ  [ 25 – 27 ] 
 Hepcidin  Biomarker of iron metabolism in 
blood and urine 
 Clinical grade  SELDI-TOF-MS 
 MALDI-TOF MS 
 Ion trap 
 QqQ 
 [ 16 ,  28 – 36 ] 
 Human Serum Inter-Trypsin 
Inhibitor Heavy Chain 4 (ITIH4) 
 Cancer biomarker  Research  SELDI TOF 
 QqQ 
 [ 37 ,  38 ] 
 Pro-gastrin-releasing peptide 
(ProGRP) 
 Diagnosis of bronchial cancer-small 
cell cancer 
 Research  Q, QqQ  [39 ] 
 Xylosyltransferase I activity  Biomarker for connective tissue 
disease 
 Research  QqQ  [40 ] 
 Urinary albumin  Biomarker of kidney function  Clinical grade  QqQ  [41 ] 
 45 Proteins in human plasma  Plasma proteins including 
biomarkers of cardiovascular 
disease 
 Clinical grade  Q-TRAP  [42 ] 
 AHSG protein and AHSG 
phosphopeptide 
 Biomarker for hepatocellular 
carcinoma 
 Research  QqQ 
 Orbitrap 
 [43 ] 
 Amyloid peptides in cerebrospinal 
fluid 




 Ion trap, QqQ 
 Q-TRAP 
 [ 44 – 54 ] 
 A-I and B Apolipoproteins  Cardiovascular risk prediction  Clinical grade  QqQ  [15 ] 
 Apolipoprotein E (ApoE)  Cardiovascular risk/Alzheimer risk  Research and 
clinical grade 
 Ion trap  [55 ] 
 Bradykinin, fibrinogen fragments, 
inter-trypsin inhibitor heavy chain 4 
and complement component 4a 
 Potential biomarkers for breast 
cancer 
 Research  QqQ  [38 ] 
 Cystatin C  Biomarker for kidney function  Research  Q-TOF  [56 ] 
 Hemoglobin  Hemoglobinopathy  Research and 
clinical grade 
 ETD   – Ion trap  [57 ] 
 IGFBP-3 and IGF-1  Hormone detection (abuse)  Research  QqQ 
 QTRAP 
 [ 58 ,  59 ] 
 NT-proBNP, MRP14, BNP-32, 
Troponin I, CRP, sCD40L, IL-33, 
Troponin T, MPO and Interleukin-33 
 Biomarkers of cardiovascular 
disease 
 Research  QqQ 
 Q-TRAP 
 [ 60 ,  61 ] 
 Oxytocin  Neuropeptide hormone  Research  QqQ  [62 ] 
 Proapolipoprotein A-I, transferrin, 
hemoglobin, apolipoprotein 
A-I, apolipoprotein C-III, and 
haptoglobin a2chain 
 Blood proteins including biomarkers 
for breast cancer 
 Research  MALDI-TOF/
TOF 
 [63 ] 
 Prostate specific antigen  Biomarker for prostate cancer  Clinical grade  Q-TRAP  [ 64 ,  65 ] 
 Zn- 2 glycoprot é ine  Potential biomarker for prostate 
cancer 
 Research  QqQ  [66 ] 
 Table   1    Analytes that have been the subject of qCCP type analyses. 
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decrease with increasing  m/z, and limited dynamic ranges 
( Table    2 ). Due to the complexity of biological fluids, this 
approach often necessitates efficient prefractionation/
purification of the analytes of interest before analysis. 
This has been done, e.g., for amyloid peptides following 
immunopurification [73 ]. 
 A potentially interesting variation of MALDI-TOF is 
embodied by SELDI-TOF, which uses activated chromato-
graphic surfaces [hydrophobic, hydrophilic, ion exchange, 
immobilized metal affinity chromatography (IMAC)] on 
chips to prefractionate protein samples before detection. 
This procedure selects a subset of the proteome based on 
physicochemical properties [74 ]. SELDI-TOF has a higher 
throughput than other methods of MS but it is limited by 
its poor ability to accurately and specifically detect low 
abundant proteins. It has been widely used to identify dif-
ferences in the protein expression profiles of two or more 
distinct clinical samples and to quantify previously recog-
nized biomarkers of disease. More specifically, immuno-
capture on the chips has been used to detect  β -amyloid 
peptides in cerebrospinal fluid [44 ]. IMAC has been used 
to quantify hepcidin [75 ]. 
 Electrospray ionization (ESI) 
mass spectrometer 
 This ionization method is based on the formation of drop-
lets/spray at the end of the ESI capillary subjected to a 
high electrical potential. HPLC is used upfront to deliver 
a fractionated sample. HPLC relies on different types 
of stationary phases contained in columns and a pump 
system that moves the sample in a mobile phase through 
the column. In MS focused on peptides, a reversed phase 
HPLC column with a non-polar stationary phase and an 
aqueous, moderately polar mobile phase is generally 
used. Different pressures and flow rates are used, ranging 
from hundreds to  > 10,000 PSI and hundreds (normal 
flow) to  < 1  μ L/min (nano-flow), respectively. At the end of 
the capillary, an intense electric field ionizes molecules in 
progressively shrinking droplets (shrinkage due to solvent 
evaporation and Coulombic repulsion) ultimately leading 
to unsolvated protonated or deprotonated analyte ions. 
The ions that are generated, often with multiple charges, 
are guided using electrical potentials in a vacuum. Differ-
ent MS systems separate ions based on  m/z via different 
mechanisms and detect them. In most cases relevant to 
qCCP, ionized analytes are fragmented by collision with a 
gas and the fragments are detected and quantified in an 
experiment termed tandem or MS/MS (or MS2) analysis. 
 Ion trap 
 Ion trap mass spectrometers analyze and fragment ions 
in the same space bounded generally by three electrodes. 
A radio frequency with or without a continuous voltage 
tension is used to capture ions. A scan of the radio fre-
quency amplitude leads to expulsion of ions with specific 
 m/z to a detector. MS2 analysis is possible after ion frag-
mentation using a radio frequency corresponding to ion 
resonance frequency. Resulting fragment ions are then 
trapped and can themselves be the subject of successive 
fragmentation (MS n ). These systems are very efficient for 
the identification of peptides and were initially used in 
early qCCP studies ( Table    1 ). The narrow dynamic range 
of ion trap mass spectrometers has generally limited their 
use in more recent qCCP efforts ( Table    2 ). However, ion 
trapping devices offer the possibility to easily manipu-
late ions, such as performing ion-ion reactions. This 
opens news perspective for qCCP, such as the analysis of 
full-length proteins in an SRM-type of operation but with 
electron capture dissociation (ETD) instead of collision-
induced dissociation (CID) [31]. As illustrated in  Figure   2 , 
this approach can efficiently be used to address specific 
needs in qCCP. 
  Triple Quadrupoles 
(QqQ) 
 Quadrupole 
 TOF (Q-TOF) 
 Quadrupole 
 Orbitrap 
 Ion trap  Orbitrap  FT-ICR  MALDI 
TOF/TOF 
 Selectivity/specificity  High  Very high  Very high  High  Very high  Very high  Very high 
 Dynamic range  Very high  High  High  Low  Medium  Medium  Medium 
 SRM/MRM  Very high  n/a  High  High  n/a  n/a  n/a 
 Profile/Full scan  Low  Very high  Very high  low  High  Very high  n/a 
 Robustness  Very high  Medium  Medium  Very high  Medium  Medium  High 
 Cost  + + +  + + + +  + + +  + +  + + +  + + + + +  + + + 
 Use for qCCP  Very high  High  High  Low  Medium  Low  Low 
Table   2    Mass spectrometer type and their characteristics with regards to qCCP. 
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 The quantitation of the amount of peptide/protein 
present in a biological sample in MS relies on the prin-
ciple of isotope dilution. A known quantity of a stable 
isotope labeled internal standard might be added at dif-
ferent steps of the MS analytical workflow (see the text for 
details). 
 Triple quadrupoles (ESI-QqQ) 
 A single quadrupole (Q) is composed of four electrodes 
with a voltage potential difference that creates a quad-
rupolar electric field. By adjusting the voltage potentials 
between electrodes, one can control the trajectory of an 
ion entering the Q. Only ions with specific  m/z will have 
a stable trajectory and reach the detector. Voltage scan-
ning allows the detection of many ions across a wide mass 
range. QqQ mass spectrometers have two Q analyzers in 
series, separated by a collision cell, which has a slightly 
different design. This combination of Qs allows for simple 
MS experiments or in tandem experiments, which is the 
configuration most used in qCCP ( Table    1 ). Briefly, the 
peptide of interest is selected in the first Q, fragmented 
in the second, and a specific fragment is detected after 
the third Q, which acts as a filter. This technology permits 
the highly sensitive, targeted detection and quantitation 
of a panel of peptides with very good selectivity, even in 
complex mixtures [77 ]. 
 Of note, hybrid systems combining QqQ and ion trap 
(Q-TRAP) have been developed. These systems permit the 
specific quantitation of low abundant ions through an addi-
tional  ‘ MS 3 ’ fragmentation step in the ion trap. This approach 
in has been used to quantify prostate specific antigen (PSA) 
in non-depleted human serum with satisfactory linearity 
(10 – 1000  μ g/L), sensitivity, and selecti vity [64 ]. 
 ESI-Q-TOF 
 These hybrid systems consist of a double Q (one analyzer 
and one collision cell) followed by a TOF device. The Qs in 
series provide for high MS/MS efficiency, while the TOF pro-
vides excellent mass accuracy/resolution and high speed 
of analysis. This represents a high-resolution MS system 
(HRMS) that makes it possible to obtain full scan precursor 
 Figure   2   Principle and example of protein pseudo-SRM-ETD.
 (A) In an ion trap, a fixed  m/z ratio corresponding to a multiply charged protein precursor ion is selected, isolated and activated with ETD, and 
the fragment ion spectrum is recorded. Next, an  m/z corresponding to another protein is selected, etc. With current instrument acquisition 
frequency, about five proteins can be monitored this way. B) Once the chromatographic analysis is terminated, specific fragment-ion chromato-
grams from specific precursor-ion channels are extracted. These chromatograms correspond to specific precursor  m/z   – fragment ion  m/z transi-
tion, as in conventional SRM assays. However, as the full tandem mass spectra are acquired in time rather than a specific fragment ion signal 
in space like in conventional triple quadruple (QqQ) instruments, the method is referred to as pseudo-SRM [76 ]. C) The pseudo-SRM ETD assay 
is illustrated on human hemoglobin variants. The upper chromatogram shows a transition corresponding to the  α chain of hemoglobin. The 
second chromatogram shows a transition specific to the non-mutated  β chain. The third chromatogram shows a transition specific to a mutated 
 β chain (Hemoglobin C, Glu6  → Lys). In this example, the patient is homozygote for hemoglobin C as no wild-type  β chain is detected. With this 
technique, subtle differences in full length protein sequences can be specifically tested. Although the  β chain of hemoglobin C differs by only 
one Dalton from normal hemoglobin, both chains can be distinguished with high specificity using an ion trap device operating at nominal mass 
accuracy and resolution. The small interference observed in hemoglobin A β chain corresponds to the second isotopic peak of hemoglobin C 
 fragments. To distinguish the two proteins at the precursor ion level, ultra-high resolution instrumentation would be necessary [57 ].  
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MS data at high resolution and also obtain peptide frag-
ment data for identification. The high-resolution data have 
been used to compare the differences in peptide/protein 
quantities in body fluids and tissue samples in experiments 
that use either labeling or label free approaches ( Table   1 ). 
 Orbitrap 
 This system includes two electrodes, one spindle-shaped 
placed coaxially inside another resulting in a quadro-
logarithmic electrostatic field. The current induced by ion 
oscillations generates a radio frequency that can be decon-
volved into  m/z ion counts by Fourier transformation. This 
is comparable to Fourier transform ion cyclotron resonance 
(FTICR) MS, which is more precise but very expensive (to 
purchase and operate), therefore less compatible with 
qCCP. The orbitrap is a second example of HRMS. It is there-
fore possible to acquire full scan data of many precursor 
ions and then quantify specific fragments. Orbitraps are 
often placed in series with MS analyzers that have a faster 
cycle time. A hybrid system combining a quadrupole in 
front of an orbitrap system (Q-Orbitrap) is now available. 
This new approach with great potential is a way to combine 
the sensitivity of the Q and the specificity of the orbitrap. 
 Mass spectrometer system 
selection for qCCP 
 Table    2 summarizes the main features of the analyti-
cal systems that can be used in qCCP. Looking at previ-
ous publications in the field ( Table    1 ), we note that QqQ 
systems are most often used. They provide sensitive and 
selective detection of analytes, which is compatible with 
qCCP. The appearance of hybrid and HRMS systems with 
their multiplex potential represents an interesting devel-
opment. Importantly, analytical performance of a system 
must be sufficient to handle the detection of analytes in 
complex samples, such as biological fluids, but many 
other factors are important (e.g., preanalytical variables, 
automation, coupling to HPLC, robustness). The dynamic 
signal range of the system, typically limited in TOF and 
ion traps when compared to Qs, is also a major issue espe-
cially with the perspective of multiplex analyses. 
 One additional issue is represented by the type of 
HPLC system since it will determine the throughput and 
the volume of sample used. Micro-HPLC systems are fast 
and reliable but need much higher volume of sample than 
capillary or nano-systems. The latter are very sensitive, 
they use very small volumes of samples, but they are less 
robust. The software environment, the data management 
system, the ability of the vendor to provide IVD-certified 
equipment and to ensure clinical grade service and main-
tenance are also important. Finally, based on our under-
standing of the hospital environment, it is likely that in 
the end, the choice of a system will not be on the pure ana-
lytical performance, but rather on the cost and capacity 
of the equipment and the availability of validated reagent 
kits that are clinically ready to use out-of-the-box. 
 Quantitative measurement, 
standard and reference material 
 Quantitation and software 
 MS quantitation can be performed by comparing samples 
after metabolic or chemical labeling using isotopes or tags 
[78 ]. This is not well-adapted to qCCP, where the goal is to 
have a robust and reproducible method that can apply on 
a large number of clinical samples. Label-free approaches 
have been widely used in biomarker discovery (pre-qCCP) 
experiments. One way to perform such quantitation is 
via comparison of signal intensities, peak areas, or the 
frequency of MS/MS events attributed to peptides of a 
given protein, an approach referred to as  ‘ spectral count-
ing ’ [79 ]. A considerable disadvantage of label-free quan-
tification is its susceptibility to errors due to variability 
in HPLC/MS runs, its rather extensive workflow, and the 
statistical analyses that are required [80 ]. 
 For proteomics and qCCP applications, software is 
needed that would allow MRM quantification of pro-
teomics data while also utilizing factors such as: protein 
sequence, sequence annotation, functional annotation, 
public database of information like MS/MS spectra of 
detectable tryptic peptides, with peak areas, retention 
time, and internal standards. To achieve that, vendors 
propose software with various features that are gene-
rally restricted to the raw data from their own platforms. 
Alternatively, a public software called Skyline, is free and 
compatible with all vendors ’ file formats [80 ]. Skyline can 
be used to design SRM/MRM methods based on protein 
sequences and user-defined rules. It deals also with 
label-free methods [81 ]. It integrates SRM/MRM results 
to refine the initial method and can be used to compute 
absolute quantification based on calibration curves [82 ]. 
Skyline is getting the leading software as it facilitated 
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incre dible progress in the field of clinical proteomics and 
has brought qCCP closer to clinical laboratories than any 
other software advance. 
 Absolute quantification strategies 
 From a clinical perspective, it is important to achieve 
absolute quantitation of the amount of peptide/protein 
present in a biological sample. Isotope dilution is prob-
ably the method of choice for qCCP, because it includes 
the addition to the sample of a known quantity of an inter-
nal standard only modified by the incorporation of stable 
isotopes (e.g., 13C, 15N) ( Figure   2 ). 
 One approach uses stable isotope-labeled standard 
(SIS) peptides [ 13 ,  83 ] as internal standards (Figure 3). 
 Typically, after the tryptic digestion of sample, SIS pep-
tides are added in known quantities. Native and SIS pep-
tides are detected at roughly the same retention time and 
have comparable ionization properties, but are easily 
distinguished by the difference in mass due to isotopic 
labeling. 
 The amount of native peptide in a tryptic digest can 
be determined from the intensity ratio to the SIS peptide 
present in known quantities using external calibration. 
To help confirm the quantification, a second peptide from 










 Figure   3   Absolute quantification strategies. 
approach has been widely used for the quantification of 
proteins following enzymatic digestion [ 15 ,  21 ,  60 ]. Such 
SIS peptides are produced by chemical synthesis and are 
readily available commercially, which explains the ease of 
implementation of this method. 
 The SIS approach has however limitations, mainly due 
to  the fact that SIS peptides added in the final phase of 
sample preparation correct for bias in the analytical meas-
urement and not throughout sample preparation (notably, 
during enzymatic digestion). An alternative approach 
attempts to control for variability at the digestion step using 
a prokaryotic expression system ( Escherichia coli ) and stable 
isotope-labeled amino acids to express a protein correspond-
ing to the concatamer of the tryptic peptides of interest [84 ]. 
This polypeptide sequence is then added to the sample prior 
to tryptic digestion (Figure 3). One can then use the liber-
ated peptides from the concatamer as internal standards, an 
approach therefore particularly well-suited for multiplexed 
analysis of many proteins [12 ]. However, the method is still 
subject to the potential bias in that a partial synthetic poly-
peptide sequence may not be digested similar to a complete 
protein. Differences in denaturation could lead to retained 
secondary structure or protein-protein interactions. Other-
wise, it is possible to use isotopically-labeled whole proteins 
which are more biochemically similar to the endogenous 
targets. They can be synthesized in culture [85 ] or in  ‘ Cell-
Free ’ paradigms [86 ], purified, and then added prior to any 
treatment of the sample (Figure 3). This approach can theo-
retically help control for variability at all steps in the process 
except that variability that is due to post-translational 
 modifications not present in the expression systems. 
 Criteria for selecting analytes for qCCP 
 The choice of a target analyte for qCCP must meet many 
criteria related to patient sampling, analytical conditions, 
medical benefit and monetary cost. Our consideration 
will be based on the hypothesis that qCPP will be imple-
mented in a large number of laboratories and for a signifi-
cant number of patients. 
 Preanalytical and pretreatment issues, 
analytical/medical/economic issues 
 As mentioned previously it is important that the qCCP 
analysis be compatible with most routine analyses of 
patient samples. In other words the preanalytical pro-
cesses needed to achieve satisfactory analytical values 
(e.g., reproducibility, limit of detection/quantitation) 
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need to resemble those required for the analytes already 
measured in biological fluids of interest (i.e., blood, urine, 
etc.). For example, the need for a specific collection tube 
containing proteinase/phosphatase inhibitors, or antioxi-
dants could have a strong negative impact on the cost of 
analysis and may make qCCP for that analyte unfeasible. 
 Analytical issues 
 It is clear that qCCP analyses must reach a satisfactory 
level of analytical performance in terms of repeatability, 
robustness, reproducibility, and limits of detection. These 
features are often measured in research laboratories and 
on different proteomic platforms. However, there is a risk 
that these data will not be repeated in clinical laborato-
ries. In most cases these data are generated on samples 
whose diversity and preanalytical sample handling do not 
represent the real-life situation. There is therefore a large 
under-estimation of the impact of inevitable preanalytical 
variations (i.e., time of processing, refrigeration, hemo-
lysis, etc.) and of individual biological variations present 
in routine, uncontrolled, clinical samples (presence of 
inflammatory syndromes, dysglobulinemia, hyper-, hypo-
proteinemia, hemolysis, presence of xenobiotics, etc.). 
 With regard to the analytical performance in terms 
of sensitivity, there is also a huge gap between what is 
sought in a laboratory focusing on functional proteomics 
and a hospital laboratory. For clinical analytes we need 
to measure concentrations in pathophysiological ranges 
with satisfactory reproducibility, robustness and linearity. 
The detection of concentrations well below physiological 
concentrations is often unnecessary and one would rather 
select methods that have less front-end sample prepara-
tion (e.g., avoid concentration or dilution steps). 
 Of course, the medical utility of the assay must also 
be evaluated. As mentioned previously, in cases where 
the analyte is already measured with another method, 
it is possible to use the available information in terms 
of population values and thresholds after concordance 
studies and analyses using Bland and Altman plots [87 ] 
and weighted Deming regression. 
 Conclusions and perspective 
 There is no doubt that present and future technological 
developments in MS will allow the quantification of single 
or many peptides/proteins in complex biological fluids by 
qCCP methods that meet the rigorous quality standards 
set by the clinical environment. This will be facilitated by 
important knowledge generated in relevant Human Pro-
teome Organisation (HUPO) sponsored scientific initiatives. 
Working groups of the International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC), and in particular 
the one on Clinical Quantitative Mass Spectrometry Proteo-
mics (WG-cMSP) will also help in particular regarding stan-
dardization issues. The choice of whether to develop/use 
qCCP for a series of clinical analytes then becomes the criti-
cal issue. Asked another way, is there value added in using a 
qCCP analysis rather than using another available and more 
common approach? We list below some of the reasons: 
1.  If the analysis of a clinical biomarker requires 
impractical preanalytical processes or has issues in 
terms of laboratory safety (e.g., radioimmunoassay). 
2.  If existing assay methods have non-optimal sensitivity 
or specificity that limit clinical utility. This may be 
in relation with the biochemical characteristic of the 
analytes (e.g., poor immunogenicity, high assay cross-
reactivity with other analytes from a same family). 
3.  If there is an interest to include several isoforms 
of a given analyte. For example, the detection of 
polymorphisms (like for ApoE) or post-translational 
modifications (as for  β -amyloid peptides) could be 
meaningful. 
4.  If intellectual property concerns limit the availability 
of reagents or greatly inflate the cost of analysis. 
5.  If there is added value in integrating data from a 
panel of several analytes (i.e., qCCP approaches can 
be easily multiplexed compared with immunological 
approaches). 
6.  If novel biomarkers do have not existing immune-
detection methods readily available (it is likely 
less expensive to develop a qCCP assay than an 
immunochemical assay on an automated analyzer). 
 The implementation of qCCP is ongoing with several groups 
developing clinical applications for particular analytes 
(e.g., hepcidin, amyloid peptides, hemoglobin, apolipopro-
teins). This is not an easy task but this will be the first step 
in the expansion of a new MS approach which will repre-
sent, as in other clinical areas, a major analytical advance. 
 Highlights 
 –  MS is the leading analytical approach in proteomics. 
 –  Technological developments in MS increase 
analytical sensitivity and specificity to improve the 
quantitation of clinical analytes in biological fluids. 
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 –  Different MS systems (e.g., MALDI-TOF, QqQ, 
Q-TOF and Orbitrap) with different characteristics 
are compatible with and have been used for the 
quantitative detection of clinical analytes. 
 –  The use of MS for the quantitative detection of 
clinically relevant peptide/protein biomarkers 
in biological fluids will need to comply with IVD 
requirements and, which could be defined as a 
new field called quantitative Clinical Chemistry 
Proteomics (qCCP). 
 –  The choice of analytes to be handled by qCCP 
relies on many factors: feasibility of the analysis 
in a clinical environment, medical/economic 
considerations, validation of normal reference 
intervals or pathological cut-offs, availability of 
quality controls and standard material, etc. 
 Expert opinion 
 There is no doubt that present and future technological 
developments in MS will allow proteomics workflows to 
quantify single and multiple analytes in complex biologi-
cal fluids in a manner that is robust and accurate enough 
to be considered adequate in clinical chemistry laborato-
ries. This will, however, necessitate adapted preparative 
methods, efficient quality control and standardization. 
The choice to develop/use qCCP for a series of clinical ana-
lytes relies on several factors including: the replacement 
of existing analyses for analytical or economic issues; the 
capacity to detect novel biomarkers/isoforms that lack 
satisfactory immunochemical detection methods; or the 
development of panels of several relevant clinical ana-
lytes. The implementation of the first qCCP analyses is 
ongoing, and one can expect an expansion of this new MS 
approach in the near future. 
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